IL244373B - Pyrimidines inhibit fgfr4 - Google Patents
Pyrimidines inhibit fgfr4Info
- Publication number
- IL244373B IL244373B IL244373A IL24437316A IL244373B IL 244373 B IL244373 B IL 244373B IL 244373 A IL244373 A IL 244373A IL 24437316 A IL24437316 A IL 24437316A IL 244373 B IL244373 B IL 244373B
- Authority
- IL
- Israel
- Prior art keywords
- fgfr4 inhibitors
- pyrimidine
- pyrimidine fgfr4
- inhibitors
- fgfr4
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892881P | 2013-10-18 | 2013-10-18 | |
| PCT/US2014/060857 WO2015057938A1 (en) | 2013-10-18 | 2014-10-16 | Pyrimidine fgfr4 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL244373A0 IL244373A0 (en) | 2016-04-21 |
| IL244373B true IL244373B (en) | 2018-10-31 |
Family
ID=51842899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL244373A IL244373B (en) | 2013-10-18 | 2016-03-01 | Pyrimidines inhibit fgfr4 |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US9434697B2 (2) |
| EP (2) | EP3057943B1 (2) |
| JP (2) | JP6139788B2 (2) |
| KR (1) | KR101826015B1 (2) |
| CN (2) | CN110354128A (2) |
| AR (1) | AR098048A1 (2) |
| AU (2) | AU2014337291B9 (2) |
| BR (1) | BR112016008110B1 (2) |
| CA (1) | CA2924206C (2) |
| CL (1) | CL2016000918A1 (2) |
| CY (1) | CY1121129T1 (2) |
| DK (1) | DK3057943T3 (2) |
| ES (1) | ES2679521T3 (2) |
| HR (1) | HRP20181129T1 (2) |
| HU (1) | HUE039268T2 (2) |
| IL (1) | IL244373B (2) |
| JO (1) | JO3515B1 (2) |
| LT (1) | LT3057943T (2) |
| MX (1) | MX378288B (2) |
| MY (1) | MY184733A (2) |
| NZ (1) | NZ717559A (2) |
| PE (1) | PE20160679A1 (2) |
| PH (1) | PH12016500676B1 (2) |
| PL (1) | PL3057943T3 (2) |
| PT (1) | PT3057943T (2) |
| RS (1) | RS57444B1 (2) |
| RU (1) | RU2715708C2 (2) |
| SG (1) | SG11201602069WA (2) |
| SI (1) | SI3057943T1 (2) |
| SM (1) | SMT201800379T1 (2) |
| TW (1) | TWI597268B (2) |
| UA (1) | UA116920C2 (2) |
| WO (2) | WO2015057963A1 (2) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| RS58514B1 (sr) | 2012-06-13 | 2019-04-30 | Incyte Holdings Corp | Supstituisana triciklična jedinjenja kao inhibitori fgfr |
| SG11201500125QA (en) | 2012-07-11 | 2015-02-27 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| EP3943087A1 (en) | 2013-03-15 | 2022-01-26 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| CN105307657B (zh) | 2013-03-15 | 2020-07-10 | 西建卡尔有限责任公司 | 杂芳基化合物和其用途 |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| PH12016500676B1 (en) | 2013-10-18 | 2022-07-20 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
| TN2016000115A1 (en) | 2013-10-25 | 2017-07-05 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors. |
| RS63405B1 (sr) | 2013-10-25 | 2022-08-31 | Blueprint Medicines Corp | Inhibitori receptora faktora rasta fibroblasta |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| JP6585167B2 (ja) | 2014-10-03 | 2019-10-02 | ノバルティス アーゲー | Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| TWI712601B (zh) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| WO2016164703A1 (en) * | 2015-04-09 | 2016-10-13 | Eisai R & D Management Co., Ltd. | Fgfr4 inhibitors |
| KR102548229B1 (ko) * | 2015-04-14 | 2023-06-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 결정질 fgfr4 억제제 화합물 및 그의 용도 |
| CN108348519A (zh) * | 2015-07-20 | 2018-07-31 | 台北医学大学 | 经氯苯取代的氮杂芳基化合物 |
| WO2017015363A1 (en) * | 2015-07-20 | 2017-01-26 | Dana-Farber Cancer Institute, Inc. | Novel pyrimidines as egfr inhibitors and methods of treating disorders |
| CN105418441A (zh) * | 2015-12-22 | 2016-03-23 | 中国工程物理研究院化工材料研究所 | 2,3-二氯-4-羟基苯胺的制备方法 |
| WO2017118438A1 (zh) * | 2016-01-08 | 2017-07-13 | 杭州英创医药科技有限公司 | 作为fgfr抑制剂的杂环化合物 |
| JP7372740B2 (ja) * | 2016-05-10 | 2023-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ |
| CN107400092B (zh) * | 2016-05-20 | 2021-08-24 | 浙江海正药业股份有限公司 | 嘧啶类衍生物及其制备方法和其在医药上的用途 |
| CN108884097B (zh) | 2016-05-20 | 2021-05-28 | 浙江海正药业股份有限公司 | 嘧啶类衍生物、其制备方法和其在医药上的用途 |
| CN105884760B (zh) * | 2016-06-13 | 2019-01-04 | 厦门市蔚嘉化学科技有限公司 | 一种可比司他中间体的制备方法 |
| BR112019003722A2 (pt) * | 2016-08-23 | 2019-05-28 | Eisai R&D Man Co Ltd | terapias de combinação para o tratamento de carcinoma hepatocelular |
| WO2018049233A1 (en) | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
| WO2018055503A1 (en) | 2016-09-20 | 2018-03-29 | Novartis Ag | Combination comprising a pd-1 antagonist and an fgfr4 inhibitor |
| SG11201903911UA (en) | 2016-11-02 | 2019-05-30 | Novartis Ag | Combinations of fgfr4 inhibitors and bile acid sequestrants |
| CA3043948C (en) * | 2016-11-17 | 2021-08-31 | Guangdong Zhongsheng Pharmaceutical Co., Ltd | Fgfr4 inhibitor and preparation method and use thereof |
| KR101812266B1 (ko) | 2016-11-25 | 2017-12-27 | 한국과학기술연구원 | 4-((2-아크릴아미도페닐)아미노)티에노[3,2-d]피리미딘-7-카복스아미드 유도체 및 그의 약학적 활용 |
| CN108239069B (zh) * | 2016-12-26 | 2021-01-05 | 南京药捷安康生物科技有限公司 | 一种用于成纤维细胞生长因子受体的抑制剂及其用途 |
| CN108503593B (zh) * | 2017-02-28 | 2021-04-27 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| EP3663285B1 (en) * | 2017-08-04 | 2024-01-24 | Abbisko Therapeutics Co., Ltd. | Formylpyridine derivative having fgfr4 inhibitory activity, preparation method therefor and use thereof |
| CN109422760B (zh) * | 2017-09-01 | 2022-05-27 | 南京圣和药物研发有限公司 | Fgfr4抑制剂及其应用 |
| CA3074885A1 (en) * | 2017-09-05 | 2019-03-14 | Bioardis Llc | Aromatic derivative, preparation method for same, and medical applications thereof |
| MA51570A (fr) | 2018-01-10 | 2020-11-18 | Eisai R&D Man Co Ltd | Polythérapies pour le traitement du carcinome hépatocellulaire |
| HRP20241288T1 (hr) | 2018-05-04 | 2024-12-06 | Incyte Corporation | Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju |
| AU2019262579B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Salts of an FGFR inhibitor |
| CN112313207B (zh) * | 2018-06-22 | 2023-02-14 | 北京赛特明强医药科技有限公司 | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 |
| WO2020177067A1 (en) | 2019-03-05 | 2020-09-10 | Bioardis Llc | Aromatic derivatives, preparation methods, and medical uses thereof |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11518758B2 (en) | 2019-05-10 | 2022-12-06 | Deciphera Pharmaceuticals, Llc | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| PE20220597A1 (es) | 2019-05-10 | 2022-04-22 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos |
| PE20221083A1 (es) | 2019-06-17 | 2022-07-05 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN112341344B (zh) * | 2019-08-09 | 2021-10-26 | 上海喀露蓝科技有限公司 | 一种激酶抑制剂中间体的制备方法 |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP7832891B2 (ja) | 2019-12-04 | 2026-03-18 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| KR102797616B1 (ko) * | 2019-12-23 | 2025-04-21 | 베이징 사이텍-엠큐 파마슈티컬즈 리미티드 | 시아노-치환된 피리딘 및 시아노-치환된 피리미딘 화합물 및 이의 제조방법 및 이의 적용 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US20230172867A1 (en) | 2020-05-15 | 2023-06-08 | Eisai R&D Management Co., Ltd. | A method for treating cancer with an oral dosage form of an fgfr4 inhibitor |
| JP2023533903A (ja) * | 2020-05-15 | 2023-08-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｆｇｆｒ４阻害剤の経口製剤によるがんの治療方法 |
| CN113943251B (zh) * | 2020-07-16 | 2026-04-17 | 正大天晴药业集团股份有限公司 | 双环庚烯基氨基取代的氮杂芳环类化合物及其医药用途 |
| US20230398227A1 (en) | 2020-10-05 | 2023-12-14 | Chiome Bioscience Inc. | Medicine for treating cancer |
| CN114621106A (zh) * | 2020-12-11 | 2022-06-14 | 重庆医药工业研究院有限责任公司 | 一种酪氨酸激酶药物中间体的制备方法 |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| CN115490670A (zh) * | 2021-06-17 | 2022-12-20 | 浙江海正药业股份有限公司 | Fgfr4选择性抑制剂的盐及其制备方法和用途 |
| CN115504965A (zh) | 2021-06-23 | 2022-12-23 | 浙江海正药业股份有限公司 | 嘧啶类衍生物的晶型及其制备方法 |
| CN114276266B (zh) * | 2021-12-30 | 2024-10-11 | 兰州康鹏威耳化工有限公司 | 一种4-氨基-2-氟苯甲酰胺的制备方法 |
| CN114560815A (zh) * | 2022-03-04 | 2022-05-31 | 北京工业大学 | (2-((5-氯-取代苯基氨基嘧啶-2-基)氨基)苯基)氨基甲酸叔丁酯类衍生物 |
| CN116947825B (zh) * | 2022-04-14 | 2025-11-28 | 浙江海正药业股份有限公司 | Fgfr4选择性抑制剂化合物的晶型及其制备方法和用途 |
| CN114835640B (zh) * | 2022-05-24 | 2024-02-13 | 中国药科大学 | 成纤维细胞生长因子受体抑制剂、制备方法及应用 |
| EP4509142A1 (en) | 2023-08-16 | 2025-02-19 | Ona Therapeutics S.L. | Fgfr4 as target in cancer treatment |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0310550B1 (de) * | 1987-09-28 | 1993-05-26 | Ciba-Geigy Ag | Schädlingsbekämpfungsmittel |
| TR200003429T2 (tr) | 1998-05-26 | 2001-07-23 | Warner-Lambert Company | Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler. |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| AU2003285012A1 (en) | 2002-10-24 | 2004-05-13 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| WO2005011597A2 (en) | 2003-07-29 | 2005-02-10 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| WO2006038112A1 (en) | 2004-10-01 | 2006-04-13 | Warner-Lambert Company Llc | Use of kinase inhibitors to promote neochondrogenesis |
| GEP20105074B (en) * | 2005-12-21 | 2010-09-10 | Novartis Ag | Pyrimidinyl aryl urea derivatives being fgf inhibitors |
| EP1918376A1 (en) | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| PT2114900T (pt) * | 2007-01-31 | 2019-01-17 | Ym Biosciences Australia Pty | Compostos à base de tiopirimidina e as suas utilizações |
| US20090062320A1 (en) | 2007-08-28 | 2009-03-05 | Vito Guagnano | Method of Treating Disorders Mediated by the Fibroblast Growth Factor Receptor |
| NZ603525A (en) * | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| WO2011090738A2 (en) | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| RU2012134637A (ru) | 2010-01-14 | 2014-02-20 | Йейл Юниверсити | Ингибиторы рецепторных тирозинкиназ (rtk) и способы их применения |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| AR085934A1 (es) | 2011-04-08 | 2013-11-06 | Ab Science | Tratamiento de mieloma multiple con masitinib |
| CN102816162B (zh) | 2011-06-10 | 2016-04-27 | 中国科学院广州生物医药与健康研究院 | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 |
| JP2015506944A (ja) | 2012-01-18 | 2015-03-05 | ジェネンテック， インコーポレイテッド | Ｆｇｆ１９修飾薬を使用する方法 |
| KR102032007B1 (ko) | 2012-02-28 | 2019-10-14 | 아스텔라스세이야쿠 가부시키가이샤 | 질소 함유 방향족 헤테로환 화합물 |
| SG11201500125QA (en) * | 2012-07-11 | 2015-02-27 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| CA2908098A1 (en) * | 2013-03-15 | 2014-09-25 | Celgene Avilomics Research, Inc. | Mk2 inhibitors and uses thereof |
| CN105307657B (zh) * | 2013-03-15 | 2020-07-10 | 西建卡尔有限责任公司 | 杂芳基化合物和其用途 |
| US9783504B2 (en) | 2013-07-09 | 2017-10-10 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| AR097455A1 (es) | 2013-08-28 | 2016-03-16 | Astellas Pharma Inc | Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo |
| PH12016500676B1 (en) * | 2013-10-18 | 2022-07-20 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
| RS63405B1 (sr) | 2013-10-25 | 2022-08-31 | Blueprint Medicines Corp | Inhibitori receptora faktora rasta fibroblasta |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| CN113105454B (zh) | 2016-05-20 | 2022-10-11 | 江苏豪森药业集团有限公司 | Fgfr4抑制剂、其制备方法和应用 |
| CN108884097B (zh) | 2016-05-20 | 2021-05-28 | 浙江海正药业股份有限公司 | 嘧啶类衍生物、其制备方法和其在医药上的用途 |
-
2014
- 2014-10-16 PH PH1/2016/500676A patent/PH12016500676B1/en unknown
- 2014-10-16 DK DK14790956.8T patent/DK3057943T3/en active
- 2014-10-16 AR ARP140103845A patent/AR098048A1/es active IP Right Grant
- 2014-10-16 AU AU2014337291A patent/AU2014337291B9/en active Active
- 2014-10-16 PE PE2016000460A patent/PE20160679A1/es unknown
- 2014-10-16 HR HRP20181129TT patent/HRP20181129T1/hr unknown
- 2014-10-16 JP JP2016523266A patent/JP6139788B2/ja active Active
- 2014-10-16 ES ES14790956.8T patent/ES2679521T3/es active Active
- 2014-10-16 RU RU2016118981A patent/RU2715708C2/ru active
- 2014-10-16 WO PCT/US2014/060902 patent/WO2015057963A1/en not_active Ceased
- 2014-10-16 WO PCT/US2014/060857 patent/WO2015057938A1/en not_active Ceased
- 2014-10-16 EP EP14790956.8A patent/EP3057943B1/en active Active
- 2014-10-16 JO JOP/2014/0297A patent/JO3515B1/ar active
- 2014-10-16 SG SG11201602069WA patent/SG11201602069WA/en unknown
- 2014-10-16 KR KR1020167009625A patent/KR101826015B1/ko active Active
- 2014-10-16 TW TW103135880A patent/TWI597268B/zh active
- 2014-10-16 PL PL14790956T patent/PL3057943T3/pl unknown
- 2014-10-16 BR BR112016008110-2A patent/BR112016008110B1/pt active IP Right Grant
- 2014-10-16 HU HUE14790956A patent/HUE039268T2/hu unknown
- 2014-10-16 LT LTEP14790956.8T patent/LT3057943T/lt unknown
- 2014-10-16 SM SM20180379T patent/SMT201800379T1/it unknown
- 2014-10-16 NZ NZ717559A patent/NZ717559A/en unknown
- 2014-10-16 RS RS20180834A patent/RS57444B1/sr unknown
- 2014-10-16 MX MX2016004933A patent/MX378288B/es unknown
- 2014-10-16 EP EP18167989.5A patent/EP3421457B1/en active Active
- 2014-10-16 PT PT147909568T patent/PT3057943T/pt unknown
- 2014-10-16 MY MYPI2016000489A patent/MY184733A/en unknown
- 2014-10-16 CN CN201910565163.7A patent/CN110354128A/zh active Pending
- 2014-10-16 SI SI201430792T patent/SI3057943T1/en unknown
- 2014-10-16 CA CA2924206A patent/CA2924206C/en active Active
- 2014-10-16 CN CN201480056358.4A patent/CN105899490B/zh active Active
- 2014-10-16 UA UAA201605322A patent/UA116920C2/uk unknown
-
2016
- 2016-01-19 US US15/000,659 patent/US9434697B2/en active Active
- 2016-03-01 IL IL244373A patent/IL244373B/en active IP Right Grant
- 2016-04-18 CL CL2016000918A patent/CL2016000918A1/es unknown
- 2016-07-27 US US15/221,018 patent/US9730931B2/en active Active
-
2017
- 2017-04-27 JP JP2017088732A patent/JP2017160233A/ja active Pending
- 2017-06-20 US US15/627,851 patent/US10537571B2/en active Active
-
2018
- 2018-07-18 CY CY181100754T patent/CY1121129T1/el unknown
- 2018-11-27 AU AU2018271284A patent/AU2018271284B2/en active Active
-
2019
- 2019-12-17 US US16/717,080 patent/US10912774B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL244373B (en) | Pyrimidines inhibit fgfr4 | |
| ZA201601697B (en) | Substituted pyrimidine bmi-1 inhibitors | |
| ZA201603337B (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| LT3057959T (lt) | Dnr-pk inhibitoriai | |
| SG11201507203RA (en) | Dna-pk inhibitors | |
| IL245846A0 (en) | syk inhibitors | |
| IL243578A0 (en) | syk inhibitors | |
| SG11201600062RA (en) | Pyrimidine derivatives as kinase inhibitors | |
| GB201303109D0 (en) | Novel pyrimidine compounds | |
| ZA201506156B (en) | Novel inhibitors | |
| EP2903970A4 (en) | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS | |
| GB201313664D0 (en) | Bcl-3 inhibitors | |
| SG11201507040VA (en) | Predicting response to egfr inhibitors | |
| GB201307155D0 (en) | Kinase inhibitors | |
| GB201316711D0 (en) | Glycobiological surfaces |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |